

REMARKS/ARGUMENTS

Claims 1-6 and 40-41 are now pending in the application. Claims 1-6 are currently amended and claims 7-39 and 42-46 are cancelled, without prejudice or disclaimer of any previously claimed subject matter.

Claims 1-6 have been amended to reflect the elected subject matter. The amendments to claim 1 find support in original claim 12, and dependent claims 2-4 further limit the subject matter in claim 1. Claims 5-6 recite specific compounds which are presented in Examples 12 and 13 on pages 63 and 64 of the specification, respectively. No new matter has been added.

In the Office Action dated June 14, 2007, the Examiner restricted the prosecution of the application to one of five groups proposed by the Examiner:

I. Claims 1-2, 6-7, 14, 17, and 40-41 drawn to products of formula (I) where Z is not a covalent single or double bond between X' and Y' or a composition comprising said product;

II. Claims 1-13, 18-21, 24-25, 27-29, 31-33 and 40-41 drawn to products of formula (I) where Z is a covalent single or double bond between X' and Y'; X is -O-; Y is -O-; X' and Y' are -C(R₅)₂- or a composition comprising the said product;

III. Claims 1-13, 18-21, 24-25, 27-29, 31-33 and 40-41 drawn to products of formula (I) where Z is a covalent single or double bond between X' and Y'; X is -O-; Y is -N(R₁₈)-, or X is -N(R₁₈)-; Y is -O-; X' and Y' are C(R₅)₂-, or a composition comprising the said product;

IV. Claims 1-13, 18-21, 24-25, 27-29, 31-33 and 40-41 drawn to products of formula (I) wherein Z is a covalent single or double bond between X' and Y'; X is -N(R₁₈)-; Y is -N(R₁₈)-; X' and Y' are -C(R₅)₂- or a composition comprising the said product;

V. Claims 34-39 and 42-46 drawn to a method of using said compound or composition for the treatment of various diseases or disorders.

The Examiner also indicated that Applicants may choose to elect a single invention of similar scope as Groups I-V set forth by the Examiner by identifying another specific embodiment.

In accordance with the option to select a different group of similar scope to Groups I-V set forth by the Examiner, Applicants elect the embodiment drawn to products of formula (I) where Z represents a covalent single bond between X' and Y'; X and X' taken together form -C(R₅)=N-; Y' is -N(R₅)-; and Y is -C(R₅)- and taken together with the carbon atom bearing the

phenyl ring forms a double bond. The elected subject matter represents a compound of formula (I) where variables X, X', Y, Y' and Z form a pyrazole ring.

The Examiner has also required that Applicants select a single compound as the elected species for initial search purposes. Applicants select the compound 1-(3-Methylbutyl)-4-(4-methylphenyl)-1*H*-pyrazole, which is shown in Example 13 on page 64 of the specification (compound 13). Claims 1-6 and 40-41 read on the selected species.

Conclusion

In conclusion, Applicant believes that the claims are in condition for allowance. A Notice of Allowance is therefore respectfully solicited. If the Examiner believes any informalities remain in the application, which may be corrected by Examiner's Amendment, whether any other issues can be resolved by telephone interview, telephone call with the undersigned attorney at (404) 572-2458 is courteously solicited. The Commissioner is authorized to charge any deficiency to Deposit Account 11-0980.

Respectfully submitted,

Date: December 12, 2007

/John Esteban Ezcurra/

KING & SPALDING LLP
1180 Peachtree Street
34th Floor
Atlanta, Georgia 30309
Tel.: (404) 572-2458

John Esteban Ezcurra
Reg. No. 61,004